TABLE OF CONTENTS
Visual tracking of 3D targets
Genotype calling and phasing software
Technologies for improved gasoline production
Complement alternative pathway inhibitor
3D reconstruction and tracking for mobile devices
Fluid biomarker for diagnosis of joint injuries
Complement C5 inhibitor
Tethered enzymatic reactions
Improved treatment for brain tumours
TFMGs on syringe needles
3D visual tracking with applications such as augmented reality and robotic control.
A fast, scalable, and highly parallelisable genotype prediction method.
Platform technologies for the improved processing of fluid catalytic cracking (FCC) gasoline.
Inhibiting a key step in the alternative complement pathway with this novel tick-derived polypeptide inhibitor.
A multi-platform framework which enables real-time 3D dense reconstruction and tracking of a very large space.
A quantitative method using biomarkers to distinguish between end-stage joint injuries and inflammatory arthritis.
Oxford researchers have identified a novel tick-derived polypeptide inhibitor of complement C5.
An innovative method to study tethered enzymatic reactions that are prevalent in cell signalling.
A Taiwanese research team has developed a traceable brain tumour therapy using radioactive gold nanoparticles.
A new coating method has been developed for achieving a low coefficient of friction (COF) on syringe needles.
Oxford Smart Glasses' offer help to near-blind people
University spinout OxSight, has reported that in a recent UK-wide trial its smart glasses helped sight impaired and blind people to navigate independently, avoid collisions and see in the dark.
New CEO for Oxford University Innovation
Dr Matt Perkins is the new CEO of Oxford University Innovation
Oxford University Innovation 2016. All rights reserved.
Edit your subscription | Unsubscribe